Steffen Borrmann,Zita Sulyok,Katja Müller,Mihaly Sulyok,Rolf Fendel,Johannes Friesen,Albert Lalremruata,Thaisa Lucas Sandri,The Trong Nguyen,Carlos Lamsfus Calle,Annette Knoblich,Javier Ibáñez,Freia-Raphaella Lorenz,Henri Lynn Heimann,David M. Weller,Regina Steuder,Selorme Adukpo,Patricia Granados Bayon,Zsófia Molnár,Meral Esen,Wolfram Metzger,Eric. R. James,Adam Ruben,Yonas Abebe,Sumana Chakravarty,Anita Manoj,KC Natasha,Tooba Murshedkar,Julius C.R. Hafalla,Tamirat Gebru Woldearegai,Fiona O’Rourke,Jana Held,Pete Billingsley,B. Kim Lee Sim,Thomas L. Richie,Peter G. Kremsner,Stephen L. Hoffman,Kai Matuschewski,Benjamin Mordmüller

Abstract:Abstract Potent protection against malaria can be induced by attenuated live-immunization with Plasmodium falciparum (Pf) sporozoites (SPZ). However, a better understanding of the critical processes involved in the establishment of protective immunity is needed. We explored the safety and vaccine efficacy of early chemo-attenuation of PfSPZ under atovaquone-proguanil (AP). AP caused early arrest of P. berghei liver stages. Despite the absence of replication, robust protection in mice correlated with parasite-specific effector-memory CD8 + T-cell responses. In a phase I clinical trial a single dose of AP prevented Pf infections in the liver of adult, human subjects who received three doses of 5.12×10 4 or 1.5×10 5 PfSPZ by direct venous inoculation combined with oral AP. However, only 2 of 8 (25%) and 2 of 10 (20%), respectively, were protected against controlled human malaria infection (CHMI) 10 weeks after the last vaccine dose, despite levels of IgG antibodies to the Pf circumsporozoite protein (PfCSP) comparable to those achieved in fully protected volunteers after immunization with 5.12×10 4 PfSPZ with chloroquine chemoprophylaxis active only against subsequent blood stages. We identify lower IgG recognition of the secreted liver stage-specific antigens LISP2 and LSA1 and the multi-stage antigen MSP5 as immune signatures of inferior vaccine efficacy compared to PfSPZ with chloroquine chemoprophylaxis. In conclusion, we show that immune signatures of liver stage antigens, but neither an established rodent malaria model nor concentrations of antibodies against the major surface protein of sporozoites, permit prediction of vaccine efficacy. Thus, this study provides a clear rationale for the development of live sporozoite vaccination protocols that boost exposure to Pf liver stage antigens. Significance Statement Our research demonstrates that attenuation of liver infection of high doses of Plasmodium falciparum sporozoites by concomitant single-dose administration of atovaquone-proguanil is safe in humans. However, vaccine efficacy was modest when compared to an identical protocol using chloroquine that acts only on the subsequent blood infection. Immune signatures of secreted P. falciparum liver stage antigens, but neither an established rodent malaria model nor concentrations of sporozoite antibodies, permit prediction of vaccine efficacy.

Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection

Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity

PfSPZ Vaccine induces focused humoral immune response in HIV positive and negative Tanzanian adults

Sporozoite immunization: Innovative Translational Science to Support the Fight against malaria

Mapping of safe and early chemo-attenuated live Plasmodium falciparum immunization identifies immune signature of vaccine efficacy

Functional Human IgA Targets a Conserved Site on Malaria Sporozoites

Immune responses associated with protection induced by chemoattenuated PfSPZ vaccine in malaria-naive Europeans

Safety and protective efficacy of PfSPZ Vaccine administered to HIV-negative and -positive Tanzanian adults

An Attenuated HSV-1-Derived Malaria Vaccine Expressing Liver-Stage Exported Proteins Induces Sterilizing Protection against Infectious Sporozoite Challenge

Long lived liver-resident memory T cells of biased specificities for abundant sporozoite antigens drive malaria protection by radiation-attenuated sporozoite vaccination

IMRAS-Immunization with Radiation-Attenuated Plasmodium Falciparum Sporozoites by Mosquito Bite: Cellular Immunity to Sporozoites, CSP, AMA1, TRAP and CelTOS

Design and Evaluation of Chimeric Plasmodium falciparum Circumsporozoite Protein-Based Malaria Vaccines

Whole-sporozoite malaria vaccines: where we are, where we are going

Sterile Immunity to Malaria after DNA Prime/Adenovirus Boost Immunization Is Associated with Effector Memory CD8+T Cells Targeting AMA1 Class I Epitopes

In vitro production of infectious Plasmodium falciparum sporozoites

CD8+ T-cell mediated anti-malaria protection induced by malaria vaccines; assessment of hepatic CD8+ T cells by SCBC assay

Naturally acquired IgG responses to Plasmodium falciparum do not target the conserved termini of the malaria vaccine candidate merozoite surface protein 2

Recombinant full-length Plasmodium falciparum circumsporozoite protein-based vaccine adjuvanted with GLA-LSQ: Results of Phase 1 testing with malaria challenge

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles

Structural and immunological differences in Plasmodium falciparum sexual stage transmission-blocking vaccines comprised of Pfs25-EPA nanoparticles

Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection